Unique ID issued by UMIN | UMIN000043547 |
---|---|
Receipt number | R000049730 |
Scientific Title | Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics are non responsive. |
Date of disclosure of the study information | 2021/03/08 |
Last modified on | 2021/03/08 09:01:21 |
Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics are non responsive.
Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics are non responsive.
Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics are non responsive.
Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics are non responsive.
Japan |
Rheumatoid Arthritis
Orthopedics |
Others
NO
The aim of this study is to examine the maintenance rate and QOL including structural remission in rheumatoid arthritis patients whose MTX alone or MTX combined with biologics is non response, especially in which a certain paeriod of filgotinib therapy with MTX reduction or drug free will be performed.
Safety,Efficacy
1.Less than 0.5 of mTSS at 24 weeks after the start of this study
2.Less than 0.5 of mTSS at 60 weeks after the start of this study
3.Less than 2.6 of DAS28CRP at 24 weeks after the start of this study
4.Less than 2.6 of DAS28CRP at 60 weeks after the start of this study
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
60 weeks
Oral administration of 200mg filgotinib daily
20 | years-old | <= |
100 | years-old | >= |
Male and Female
1.Patients who agree with participation of this study
2.Patients who are more than 20-years-old
3.Patients with filg0tinib administerable
1.Patients with administration contraindication of JAK inhibitor
2.Patients with sensitivity for filgotinib
3.Patients prior to serious infection
4.Patients with active tuberculosis
5.Patients with end-stage renal failure
6.Patients with severe liver function
7.Patients with less than 1000/mm3 of neutrofils
8.Patients with less than 500/mm3 of lymphocytes
9.Patients with less than 8g/dL of hemoglobin
10.Patients with possibilities of pregnancy or feeding
100
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Department of Orthopaedic Surgery
390-8621
Asahi3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Department of Orthopaedic Surgery
390-8621
Asahi3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
DeparShinshu University School of Medicine
Shinshu University School of Medicine
Self funding
Shinshu University School of Medicine
Asahi3-1-1, Matsumoto3908621, Japan
0263-37-2572
mdrinri@shinshu-u.ac.jp
NO
2021 | Year | 03 | Month | 08 | Day |
Unpublished
Open public recruiting
2021 | Year | 03 | Month | 04 | Day |
2021 | Year | 03 | Month | 04 | Day |
2021 | Year | 03 | Month | 08 | Day |
2024 | Year | 05 | Month | 02 | Day |
2021 | Year | 03 | Month | 08 | Day |
2021 | Year | 03 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049730
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |